A Phase III, Multi-Centre, Randomised, Placebo-Controlled Study in Combination With Ca-based P Binders in Patients With Hyperphosphatemia
A Phase III, Double-Blind, Multi-Centre, Randomised, Parallel Group Design, Placebo-Controlled, Flexible Dose Study of MCI-196 in Combination With a Ca-Based Phosphate Binder in CKD Stage V Subjects on Dialysis With Hyperphosphatemia.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Frydek-Mistek, Czech Republic
-
Ostrava, Czech Republic
-
-
-
-
-
Bordeaux, France
-
Montpelier, France
-
-
-
-
-
Aachen, Germany
-
Coburg, Germany
-
-
-
-
-
Lecco, Italy
-
Milan, Italy
-
Pavia, Italy
-
-
-
-
-
Skopje, Macedonia, The Former Yugoslav Republic of
-
-
-
-
-
Gdansk, Poland
-
Krakow, Poland
-
Lodz, Poland
-
Oswiecim, Poland
-
Poznan, Poland
-
Wejherowo, Poland
-
Wroclaw, Poland
-
-
-
-
-
Belgrade, Serbia
-
Nis, Serbia
-
Novisad, Serbia
-
-
-
-
-
Cape Town, South Africa
-
Gauteng, South Africa
-
-
-
-
-
Barcelona, Spain
-
Oviedo, Spain
-
-
-
-
-
Stevenage, United Kingdom
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female, 18 to 80 years of age.
- Stable phosphate control using Calcium-based phosphate-binding medication only.
- The subject is undergoing regular dialysis treatment.
- On a stabilised phosphorus diet.
- If female and of child-bearing potential, has a negative serum pregnancy test. Sexually active females must agree to take appropriate steps not to become pregnant.
- Male subjects must agree to use appropriate contraception.
Exclusion Criteria:
- Current clinically significant medical comorbidities, which may substantially compromise subject safety, or expose them to undue risk, or interfere significantly with study procedures and which, in the opinion of the Investigator, makes the subject unsuitable for inclusion in the study.
- Body mass index (BMI) <=16.0 kg/m2 or =>40.0 kg/m2.
- Current or a history of significant gastrointestinal motility problems
- A positive test for hepatitis B surface antigen, hepatitis C antibody or HIV 1 and 2 antibodies.
- A history of substance or alcohol abuse within the last year.
- Seizure disorders.
- Using phosphate binder medication other than calcium based phosphate binders
- Using colestyramine, colestipol or colesevelam
- A history of drug or other allergy
- Participated in a clinical study with any experimental medication in the last 30 days or an experimental biological product within the last 90 days, prior to signing of the informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 2
|
3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose
|
|
Placebo Comparator: 1
|
3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Serum phosphorus change compared to placebo from baseline to week 12.
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Both Efficacy parameters (such as LDL-cholesterol, other lipid parameters, PTH, Ca, Ca x P ion product) and safety parameters.
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MCI-196-E09
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.